PE20171060A1 - Receptores quimericos de antigeno anti-cldn y metodos de uso - Google Patents
Receptores quimericos de antigeno anti-cldn y metodos de usoInfo
- Publication number
- PE20171060A1 PE20171060A1 PE2017000813A PE2017000813A PE20171060A1 PE 20171060 A1 PE20171060 A1 PE 20171060A1 PE 2017000813 A PE2017000813 A PE 2017000813A PE 2017000813 A PE2017000813 A PE 2017000813A PE 20171060 A1 PE20171060 A1 PE 20171060A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- cldn
- chemerical
- receptors
- methods
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 1
- 102000002029 Claudin Human genes 0.000 abstract 1
- 108050009302 Claudin Proteins 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se refiere a un receptor quimerico de antigeno que comprende un dominio de union anti claudina (anti-CLDN), donde el dominio de union comprende un dominio scFv de union anti-CLDN de una region variable de cadena liviana (VL) de SEQ ID NO: 21 y una region variable de cadena pesada (VH) de SEQ ID NO: 23; o una VL de SEQ ID:25 y una VH de SEQ ID NO:27; o una VL de SEQ ID:29 y una VH de SEQ ID NO:31; o una VL de SEQ ID:33 y una VH de SEQ ID NO:35; o una VL de SEQ ID:37 y una VH de SEQ ID NO:39; o una VL de SEQ ID:41 y una VH de SEQ ID NO:43; o una VL de SEQ ID:45 y una VH de SEQ ID NO:47; o una VL de SEQ ID:49 y una VH de SEQ ID NO:51; o una VL de SEQ ID:53 y una VH de SEQ ID NO:55; o una VL de SEQ ID:57 y una VH de SEQ ID NO:59. Tambien se refiere a una composicion farmaceutica y un kit. Dicho receptor tiene utilidad en el tratamiento de cancer de pulmon
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2014/064165 WO2015069794A2 (en) | 2013-11-06 | 2014-11-05 | Novel anti-claudin antibodies and methods of use |
| US201562157928P | 2015-05-06 | 2015-05-06 | |
| US201562247108P | 2015-10-27 | 2015-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20171060A1 true PE20171060A1 (es) | 2017-07-21 |
Family
ID=55909771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017000813A PE20171060A1 (es) | 2014-11-05 | 2015-11-04 | Receptores quimericos de antigeno anti-cldn y metodos de uso |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20170334991A1 (es) |
| EP (1) | EP3215523A4 (es) |
| JP (1) | JP2017535283A (es) |
| KR (1) | KR20170085531A (es) |
| CN (1) | CN107207580A (es) |
| AU (1) | AU2015343079A1 (es) |
| BR (1) | BR112017009517A2 (es) |
| CA (1) | CA2966618A1 (es) |
| CL (1) | CL2017001118A1 (es) |
| CO (1) | CO2017005538A2 (es) |
| CR (1) | CR20170235A (es) |
| DO (1) | DOP2017000110A (es) |
| EA (1) | EA201790967A1 (es) |
| EC (1) | ECSP17031725A (es) |
| IL (1) | IL252090A0 (es) |
| MA (1) | MA40921A (es) |
| MX (1) | MX2017005797A (es) |
| PE (1) | PE20171060A1 (es) |
| PH (1) | PH12017500825A1 (es) |
| SG (1) | SG11201703669YA (es) |
| TW (1) | TW201625677A (es) |
| WO (1) | WO2016073649A1 (es) |
| ZA (1) | ZA201703471B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE029577T2 (en) | 2009-03-30 | 2017-03-28 | Eisai R&D Man Co Ltd | Liposome preparation |
| MX2016005763A (es) * | 2013-11-06 | 2016-08-19 | Stemcentrx Inc | Anticuerpos anti-claudina novedosos y metodos de uso. |
| JP7015237B2 (ja) | 2016-04-28 | 2022-02-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍の成長を抑制する方法 |
| CN110072552A (zh) * | 2016-10-14 | 2019-07-30 | 默沙东公司 | 用于治疗尿路上皮癌的pd-1拮抗剂和艾立布林的组合 |
| CA3078218C (en) | 2017-09-29 | 2023-05-16 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate |
| EP3892333A4 (en) * | 2018-12-07 | 2022-11-30 | CRAGE medical Co., Limited | Tumor combined immunotherapy |
| JP2022524906A (ja) * | 2019-01-07 | 2022-05-11 | クレージュ メディカル カンパニー，リミテッド | 細胞免疫療法の組み合わせ |
| FI3920939T3 (fi) * | 2019-02-08 | 2025-01-03 | Biontech Cell & Gene Therapies Gmbh | Kimeerisiä anigeenireseptori-modifioituja soluja hoitamaan CLDN6-ekspressoivia syöpiä |
| WO2020205759A1 (en) * | 2019-03-29 | 2020-10-08 | Pact Pharma, Inc. | Personalized neoantigen-specific adoptive cell therapies |
| AU2020273695B2 (en) | 2019-05-16 | 2024-10-31 | Qilu Pharmaceutical Co., Ltd. | Antibody against claudin 18A2 and use thereof |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| WO2021129927A1 (en) * | 2019-12-23 | 2021-07-01 | Biontech Cell & Gene Therapies Gmbh | Treatment with immune effector cells engineered to express an antigen receptor |
| US20210347847A1 (en) * | 2020-05-11 | 2021-11-11 | The Broad Institute, Inc. | Therapeutic targeting of malignant cells using tumor markers |
| CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体系统 |
| EP4302777A4 (en) * | 2021-03-05 | 2025-07-02 | Shanghai Genbase Biotechnology Co Ltd | ANTI-CLDN6 ANTIBODY AND ITS USE |
| CN114478802B (zh) * | 2022-01-28 | 2023-05-26 | 郑州大学 | 一种嵌合抗原受体及其应用 |
| CN115991770A (zh) * | 2022-05-11 | 2023-04-21 | 迈威(上海)生物科技股份有限公司 | 抗人gas6抗体或其抗原结合片段及其应用 |
| CN120225555A (zh) * | 2022-10-25 | 2025-06-27 | 恺兴生命科技(上海)有限公司 | 抗体及其应用 |
| CN117169518B (zh) * | 2023-11-03 | 2024-01-19 | 赛德特(北京)生物工程有限公司 | T淋巴细胞制剂中的cd3抗体残留物的检测方法和试剂盒 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101074261A (zh) * | 2006-04-30 | 2007-11-21 | 北京同为时代生物技术有限公司 | Trail受体1和/或trail受体2特异性抗体及其应用 |
| AU2008219972A1 (en) * | 2007-02-27 | 2008-09-04 | Forerunner Pharma Research Co., Ltd. | Pharmaceutical composition comprising anti-GRP78 antibody as active ingredient |
| EP4282428A3 (en) * | 2008-01-11 | 2024-03-20 | The University of Tokyo | Anti-cldn6 antibody |
| DK3305813T3 (da) * | 2009-11-11 | 2020-04-20 | Astellas Pharma Inc | Antistoffer, der er specifikke for claudin 6 (cldn6) |
| EP2404936A1 (en) * | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| ES2769574T3 (es) * | 2013-03-15 | 2020-06-26 | Michael C Milone | Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva |
| MX2016005763A (es) * | 2013-11-06 | 2016-08-19 | Stemcentrx Inc | Anticuerpos anti-claudina novedosos y metodos de uso. |
| CN113150110A (zh) * | 2014-04-01 | 2021-07-23 | 拜恩科技细胞&基因治疗有限公司 | 密封蛋白-6特异性免疫受体和t细胞表位 |
| WO2016180467A1 (en) * | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination |
| JP2019500335A (ja) * | 2015-12-04 | 2019-01-10 | アッヴィ・ステムセントルクス・エル・エル・シー | 新規の抗クローディン抗体及び使用方法 |
-
2015
- 2015-11-03 MA MA040921A patent/MA40921A/fr unknown
- 2015-11-04 SG SG11201703669YA patent/SG11201703669YA/en unknown
- 2015-11-04 PE PE2017000813A patent/PE20171060A1/es not_active Application Discontinuation
- 2015-11-04 EP EP15857690.0A patent/EP3215523A4/en not_active Withdrawn
- 2015-11-04 WO PCT/US2015/059106 patent/WO2016073649A1/en active Application Filing
- 2015-11-04 MX MX2017005797A patent/MX2017005797A/es unknown
- 2015-11-04 AU AU2015343079A patent/AU2015343079A1/en not_active Abandoned
- 2015-11-04 CR CR20170235A patent/CR20170235A/es unknown
- 2015-11-04 KR KR1020177015413A patent/KR20170085531A/ko not_active Withdrawn
- 2015-11-04 EA EA201790967A patent/EA201790967A1/ru unknown
- 2015-11-04 CA CA2966618A patent/CA2966618A1/en not_active Abandoned
- 2015-11-04 CN CN201580072018.5A patent/CN107207580A/zh active Pending
- 2015-11-04 JP JP2017543306A patent/JP2017535283A/ja active Pending
- 2015-11-04 US US15/524,675 patent/US20170334991A1/en not_active Abandoned
- 2015-11-04 BR BR112017009517A patent/BR112017009517A2/pt not_active Application Discontinuation
- 2015-11-05 TW TW104136552A patent/TW201625677A/zh unknown
-
2017
- 2017-05-02 DO DO2017000110A patent/DOP2017000110A/es unknown
- 2017-05-03 IL IL252090A patent/IL252090A0/en unknown
- 2017-05-04 PH PH12017500825A patent/PH12017500825A1/en unknown
- 2017-05-05 CL CL2017001118A patent/CL2017001118A1/es unknown
- 2017-05-19 ZA ZA2017/03471A patent/ZA201703471B/en unknown
- 2017-05-25 EC ECIEPI201731725A patent/ECSP17031725A/es unknown
- 2017-06-02 CO CONC2017/0005538A patent/CO2017005538A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3215523A4 (en) | 2018-06-20 |
| CA2966618A1 (en) | 2016-05-12 |
| ZA201703471B (en) | 2019-06-26 |
| MA40921A (fr) | 2017-09-12 |
| IL252090A0 (en) | 2017-07-31 |
| ECSP17031725A (es) | 2017-06-30 |
| CN107207580A (zh) | 2017-09-26 |
| EA201790967A1 (ru) | 2017-10-31 |
| PH12017500825A1 (en) | 2017-10-18 |
| CL2017001118A1 (es) | 2018-01-05 |
| DOP2017000110A (es) | 2017-05-31 |
| AU2015343079A1 (en) | 2017-05-25 |
| CO2017005538A2 (es) | 2017-10-10 |
| CR20170235A (es) | 2017-07-21 |
| US20170334991A1 (en) | 2017-11-23 |
| TW201625677A (zh) | 2016-07-16 |
| MX2017005797A (es) | 2017-10-23 |
| BR112017009517A2 (pt) | 2017-12-19 |
| EP3215523A1 (en) | 2017-09-13 |
| KR20170085531A (ko) | 2017-07-24 |
| JP2017535283A (ja) | 2017-11-30 |
| SG11201703669YA (en) | 2017-06-29 |
| WO2016073649A1 (en) | 2016-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20171060A1 (es) | Receptores quimericos de antigeno anti-cldn y metodos de uso | |
| PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
| PH12017501039A1 (en) | Antibodies targeting g-protein coupled receptor and methods of use | |
| EP3872094A3 (en) | Antibodies targeting b-cell maturation antigen and methods of use | |
| PH12017501521A1 (en) | Anti-dll3 chimeric antigen receptors and methods of use | |
| PH12017500322A1 (en) | Anti-her2 antibodies and immunoconjugates | |
| MX2021010471A (es) | Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr. | |
| PH12016501366A1 (en) | Novel anti-baff antibodies | |
| EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| MX360707B (es) | Receptor antigénico quimérico. | |
| CA2924268C (en) | Anti-alpha-synuclein antibodies and methods of use | |
| EA201790569A1 (ru) | Антитела и иммуноконъюгаты против cll-1 | |
| EP3702372A3 (en) | Anti-cd40 human antibodies | |
| AR105267A1 (es) | Anticuerpos de unión a tau | |
| AR098408A1 (es) | Anticuerpos específicos para fcrn | |
| MX2020005662A (es) | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos. | |
| MX2023006786A (es) | Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control. | |
| EA201790314A1 (ru) | Новые антитела, направленные на fc-гамма-рецептор iib и fc-эпсилон-рецептор | |
| WO2018227063A8 (en) | Anti-robo2 antibodies, compositions, methods and uses thereof | |
| AR102495A1 (es) | Anticuerpos contra el dominio 3 de la inmunoglobulina y de la mucina del linfocito t (tim3) y métodos de uso | |
| MX2019002349A (es) | Anticuerpos inmunomoduladores biespecíficos que se fijan a receptores coestimuladores y de puntos de control. | |
| AR107223A1 (es) | Anticuerpos dirigidos contra upk1b y métodos para su uso | |
| HK1243090A1 (en) | Anti-cldn chimeric antigen receptors and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |